Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
MedTech
Natera buys Foresight Diagnostics in $450M cancer testing deal
Natera has closed the transaction, which features an upfront payment of $275 million plus as much as $175 million in milestones.
Conor Hale
Dec 5, 2025 11:57am
Paradigm snags $78M to revamp CRO space, inks deal with Flatiron
Dec 4, 2025 2:35pm
Royalty's $275M financing deal for Denali drug awaiting FDA nod
Dec 4, 2025 10:20am
Crescent inks $80M Kelun deal, adding ADC to mix with bispecific
Dec 4, 2025 9:50am
AZ's latest amyloidosis pact with Neurimmune could reach $780M
Dec 4, 2025 8:00am
Théa pens $280M deal for Iolyx's phase 3-ready eye disease drug
Dec 3, 2025 8:25am